Benjamin Yerxa

Benjamin R.
Yerxa was the founder of Opus Genetics, Inc. (2021, Chief Executive Officer 2022-2024) and Envisia Therapeutics, Inc. (2013, President 2013-2017).
Current jobs include Chairman at RainBio, Inc., Independent Director at Clearside Biomedical, Inc. (2022), Director at The North Carolina Biotechnology Center (2008), Director at Vedere Bio II, Inc., President & Director at Opus Genetics, Inc. (2024), and Director at Nacuity Pharmaceuticals, Inc. (2019).
Former jobs include Chief Executive Officer at The Foundation Fighting Blindness, Inc. (2017-2022), Chief Executive Officer at Retinal Degeneration Fund (2018-2022), Director at SparingVision SAS (2017-2022), EVP, Chief Research & Development Officer at Inspire Pharmaceuticals, Inc. (2009-2010), Research Scientist at Burroughs Wellcome, Vice President-Product Development at Parion Sciences, Inc. (2010-2011), Vice President-Research & Development at Clearside Biomedical, Inc. (2011-2012), and Chief Scientific Officer at Liquidia Technologies, Inc. (2012-2015).
Education includes a doctorate from the University of California, Irvine (1993) and an undergraduate degree from the University of California San Diego (1988).